Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Fudd who wrote (11351)	3/31/2003 1:52:54 PM
From: CusterInvestor	Respond to of 48461

Hope this link works, if not I will copy excerpts: 10kwizard.com I spoke with them recently too, said research was continuing, but at that point SARS was not big news yet. No comment on state of TRIB suit...........

To: Fudd who wrote (11351)	3/31/2003 1:56:45 PM
From: Baton	Respond to of 48461

Fudd: I've got it off of Free Edgar. I spoke with someone there (Cunningham?) who seemed pretty straightforward about both their predicament (Trinity lawsuit) and their potential for huge success. I asked about working with SARS and he said they had NIH grants for specific studies and purposes and they were not able to turn on a dime into other areas with their "limited resources". I'm holding as well. Baton freeedgar.com Excerpts from the filing: STRATEGY Our strategy is to become the leader in the development of rapid, easy-to-use, cost-effective nucleic acid-based technology products. We are attempting to develop diagnostic platforms that combine all three steps of nucleic acid analysis, extraction, amplification, and detection, in user-friendly, point-of-service products. Because our technology is applicable to nearly any nucleic acid testing situation, we believe we will be able to successfully develop an extremely broad range of potential commercial and research applications using our proprietary technologies. In order to facilitate this strategy, the Company: o Divested itself of its Hemostasis business segment by selling substantially all of the assets of that business to Trinity Biotech plc in order to fully focus on the development and sale of its nucleic acid-based technology products; o Began investing more resources in research and development than in its prior operating periods. In 2001, we spent $1,372,000 on research and development. In 2002, research and development expenses increased approximately $400,000 to $1,785,000, or 30% over 2001 levels. We anticipate a decrease in research and development spending in 2003 to approximately $1,300,000 due to limited capital availability. We expect this investment will continue to advance our diagnostic platforms but based on the capital currently available to the Company, we will not be able to commercialize these technologies on our own. As a result, the Company is actively pursuing strategic relationships with third parties to assist us in bringing these technologies to the commercial market; and o Is continuing to expand its worldwide distribution network for the sale of our extraction products, as well as evaluating potential partners for the co-development and/or distribution of our diagnostic platforms. The Company is focused on directly participating in the following industry segments for nucleic acid testing: o EXTRACTION/SAMPLE PREPARATION - Total annual sales of reagents for the preparation and purification of nucleic acids in 2001 was estimated to be $760 million, and is expected to grow to over $1.3 billion annually by the year 2005. o CLINICAL DIAGNOSTICS - The total annual sales of all clinical diagnostic applications was estimated to be in excess of $21 billion in 2001. Of this total, nucleic acid-based diagnostics represented approximately 7%, or $1.5 billion. It is anticipated that the total clinical diagnostics industry will grow to over $35 billion by the year 2005. The nucleic acid segment is expected to grow at a much more rapid rate as new technologies enable new testing and render old testing methodologies obsolete.